Zimmer Biomet Holdings Inc (ZBH)
Fair ValueFundamental
63
Price
$88.83
Market Cap
$17.48B
Part 1 · What the company is worth
Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$8.51B
Trailing 12 months (through 6/30/2026)
Net Income
$807M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$1.47B
Total Equity
$12.70B
Total Liabilities
$10.39B
Current Ratio
1.69
Interest Coverage
4.17
Debt/EBITDA
3.41
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$110.62
Current Price
$88.83
Margin of Safety
+19.7%
Fair Value Range
$71.91 - $149.34
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
21.56
ROE
5.6%
P/B Ratio
1.34
P/FCF
11.12
Gross Margin
69.9%
ROIC
4.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
4.8%
WACC
6.5%
ROIC − WACC
-1.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (16)
- EPS shows upward trend
- Gross Margin 69.9%
- P/FCF 11.12
- P/B Ratio 1.34
- Debt/Equity ratio
- Operating Margin 14.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Earnings Surprise avg 3.4%
- Earnings Quality (OCF/NI) 2.16
- Share Dilution -2.6%
- Piotroski F-Score 5/9
Failed (10)
- EPS CAGR 0.47%
- Price CAGR -0.69%
- ROIC 4.8%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- ROE 6.3%
- Revenue Growth 5Y 3.2%
- Analyst Consensus 33% Buy
- Net Margin Trend 9.5% vs 10.5%
Unavailable (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Ivan Tornos | President, CEO & Chairman of the Board | 50 |
| Mr. Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 55 |
| Mr. JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | 43 |
| Mr. Kevin R. Thornal | Group President of Global Businesses & Americas | 51 |
| Mr. Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 50 |
| Mr. Shaun Braun | Senior VP & Chief Information and Technology Officer | - |
| Dr. Jonathan M. Vigdorchik M.D. | Chief Science, Technology & Medical Affairs Officer | - |
| Mr. David M. DeMartino | Senior Vice President of Investor Relations | - |
| Mr. Chad F. Phipps J.D. | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 53 |
| Ms. Angela Main | Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | - |
Audit Risk
6
Board Risk
8
Compensation Risk
8
Shareholder Rights Risk
4
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-20
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-08
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for ZBH, sourced from Markets Gazette.